Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33980053/
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received...
-
Mark Fesler4yrValuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
-
Multiple Myeloma Connect4yrPlease share your thoughts concerning overdose on oral chemotherapy.
Show More Comments
The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34013100/
Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may...
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34009622/
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response...
How to Treat High-Risk Myeloma at Diagnosis and Relapse - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34010042/
Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge...
When and How to Treat Relapsed Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34010043/
The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease...